Vipul Organics said that it has received the consent to establish for its newly constructed factory at Ambernath, Maharashtra from Maharashtra Pollution Control Board.
Posts in category Business Standard
NSE SME Saj Hotels’ IPO ends with subscription of 5 times (03-10-2024)
The offer received bids for 2.19 crore shares as against 42.50 lakh shares on offer.
Surana Solar jumps 51% in ten days (03-10-2024)
Surana Solar rallied 4.99% to Rs 65.39, extending gains for the tenth consecutive trading session.
CARE Ratings reaffirms ‘A+’ rating of Spandana Sphoorty with ‘stable’ outlook (03-10-2024)
Spandana Sphoorty Financial said CARE Ratings has reaffirmed the company’s long-term rating at ‘CARE A+’ with ‘stable’ outlook.
Nifty Auto skids 3% as Sept passenger vehicle sales slow, CV sales fall (03-10-2024)
Nifty Auto index declined 2.7 per cent in trade today amid a slowdown in PV sales and fall in CV sales
Marico gains 4%; hits new high in weak market on stable volume growth in Q2 (03-10-2024)
Marico said consolidated revenue growth remained in high single digits, as higher realisations in the domestic business was offset by incremental currency headwinds in some overseas markets.
India’s external debt hits US$682.3 billion by end June 2024 (03-10-2024)
At end-June 2024, India’s external debt was placed at US$ 682.3 billion, an increase of US$ 13.3 billion over its level at end-March 2024, according to an update from RBI.
Adani Green arm inks pact to supply green power to C&I customer (03-10-2024)
Adani Green Energy (AGEL) announced that its wholly-owned subsidiary, Adani Renewable Energy Three, has entered into power consumption agreement for supply of green power to a commercial and industrial (C&I) customer.
Sobha Ltd Partly Paidup leads losers in ‘A’ group (03-10-2024)
Hindustan Petroleum Corporation Ltd, 360 ONE WAM Ltd, Dabur India Ltd and Godrej Industries Ltd are among the other losers in the BSE’s ‘A’ group today, 03 October 2024.
Auro Pharma gets USFDA nod for urinary tract infections drug. (03-10-2024)
Aurobindo Pharma announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cephalexin Tablets USP, 250 mg.